Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PDSB with free AI briefings, catalyst countdowns, and dilution alerts.

PDSB · PDS Biotechnology Corporation

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$15.2M Cash on Hand
8.3mo Cash Runway
3.4% Short Interest
$4.5 Analyst Target (2)
Follow PDSB by email Get an email when PDSB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PDSB, unsubscribe in one click. Privacy

📣 What PDSB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium… High-risk HPV Infection and Biopsy-proven CIN1 Phase 1 · NCT02065973 Completed

Also used in these trials (approved or third-party drugs, not PDSB's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PDSB holds $15.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.5M/quarter from operations, an estimated runway of 8.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PDSB files for a raise →

👥 Who Owns PDSB

Insiders 12.5% Other 5%+ holders 21.8% Institutions (70 holders) 14.8% Public and other holders 50.9%
HolderTypeShares% of sharesAs of
Nant Capital, LLC 5%+ holder (13D) 22,856,453 21.77% 2026-11-09
Patrick Soon-shiong
Director, 10% owner
Insider 13,005,334 12.39% 2026-09-14
Vanguard Capital Management LLC Institution (13F) 1,668,348 1.59% 2026-09-30
Militia Capital Management LLC Institution (13F) 1,660,578 1.58% 2026-09-30
Susquehanna International Group, LLP Institution (13F) 790,404 0.75% 2026-09-30
Renaissance Technologies, LLC Institution (13F) 621,346 0.59% 2026-09-30
Geode Capital Management, LLC Institution (13F) 616,392 0.59% 2026-09-30
Blackrock Inc. Institution (13F) 598,896 0.57% 2026-09-30
Focus Partners Wealth Institution (13F) 551,759 0.53% 2026-09-30
Quantinno Capital Management, LP Institution (13F) 551,759 0.53% 2026-09-30
Jane Street Group, LLC Institution (13F) 510,812 0.49% 2026-09-30
Vanguard Fiduciary Trust Co Institution (13F) 357,144 0.34% 2026-09-30

Share count 105,005,429 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-18
filed 2026-10-21
Dawson John Andrew
Option award (A) 22,700 – –
2026-10-18
filed 2026-10-20
Ramsdell Deborah
Option award (A) 22,700 – –
2026-10-18
filed 2026-10-20
Wendel Bruce
Option award (A) 22,700 – –
2026-01-12
filed 2026-03-03
BEDU-ADDO FRANK
Option award (A) 548,782 – –
2026-01-12
filed 2026-03-03
CONN GREGORY
Option award (A) 150,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full PDSB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PDSB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.